SEC Form 4/A · accession 0000904454-18-000697

Dicerna Pharmaceuticals Inc · DRNA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Brian K Halak

10% Owner

Period of report

Oct 30, 2018

Accepted (ET)

Nov 5, 2018 · 10:05 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001399529

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Oct 30, 2018	S	152,364	$13.68	D	3,327,511	I	By Domain Partners VIII, L.P.
Common Stock^F1,F2	Oct 30, 2018	S	1,136	$13.68	D	24,674	I	By DP VIII Associates, L.P.
Common Stock^F3,F2	Oct 30, 2018	S	90,918	$14.31	D	3,236,593	I	By Domain Partners VIII, L.P.
Common Stock^F3,F2	Oct 30, 2018	S	678	$14.31	D	23,996	I	By DP VIII Associates, L.P.
Common Stock^F4,F2	Oct 31, 2018	S	128,670	$13.60	D	3,107,923	I	By Domain Partners VIII, L.P.
Common Stock^F4,F2	Oct 31, 2018	S	959	$13.60	D	23,037	I	By DP VIII Associates, L.P.
Common Stock^F6,F5,F2	Nov 1, 2018	S	188,867	$13.37	D	2,919,056	I	By Domain Partners VIII, L.P.
Common Stock^F5,F2	Nov 1, 2018	S	1,408	$13.37	D	21,629	I	By DP VIII Associates, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.26 to $14.2499. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2The Reporting Person is a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction (4)(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his pecuniary interest therein and/or that are not actually distributed to him.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $14.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.04 to $13.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F6This amendment is being filed solely to correct a typographical error in this share number as reported in the Form 4 filed on November 1, 2018.